Ardelyx says long-term analysis supports Xphozah safety in dialysis patients

• Ardelyx presented a post hoc analysis at NKF Spring Clinical Meetings on May 7, 2026, assessing long-term safety of XPHOZAH in adults with chronic kidney disease on dialysis.
• Analysis pooled data from two open-label studies, including an 18-month extension trial and a 26-week trial, in patients whose phosphorus remained uncontrolled or who could not tolerate phosphate binders.
• Results indicated XPHOZAH lowered serum phosphate without clinically meaningful shifts in other electrolytes.
• Review also found no meaningful changes in nutrition-related biomarkers, body mass, or blood pressure over extended treatment.
• Readout supports positioning of XPHOZAH as add-on therapy with a differentiated mechanism for dialysis patients who do not reach targets on binder regimens.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ardelyx Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605070801PRIMZONEFULLFEED9715456) on May 07, 2026, and is solely responsible for the information contained therein.